XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Common Stock
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Common Stock . Common Stock

 

In July 2023, the Company entered into an agreement with BVF Partners L.P. (“BVF”) for a private placement that resulted in an aggregate net proceeds of approximately $29.7 million, after deducting issuance costs of approximately $0.3 million. In the private placement, CytomX issued pre-funded warrants to BVF to purchase up to 14,423,077 shares of common stock, accompanying Tranche 1 warrants to purchase up to 5,769,231 shares of common stock and accompanying Tranche 2 warrants to purchase up to 5,769,231 shares of common stock, at a combined price of $2.08 per share.

The following table summarizes the Company's outstanding warrants as of September 30, 2023:

 

 

 

Pre-funded Warrants

 

 

Tranche 1 Warrants

 

 

Tranche 2 Warrants

 

 

 

Number of
warrants

 

 

Weighted-
Average
Exercise Price
Per Share

 

 

Number of
warrants

 

 

Weighted-
Average
Exercise Price
Per Share

 

 

Number of
warrants

 

 

Weighted-
Average
Exercise Price
Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants Outstanding

 

 

14,423,077

 

 

$

0.00001

 

 

 

5,769,231

 

 

$

4.16

 

 

 

5,769,231

 

 

$

6.24

 

 

The pre-funded warrants will expire in July 2043, while Tranche 1 and Tranche 2 warrants will expire in July 2025 and July 2026, respectively.